- Home
- RAMP vs RCKT Comparison
RAMP vs RCKT Comparison
Compare RAMP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- RCKT
- Stock Information
- Founded
- RAMP 2018
- RCKT 1999
- Country
- RAMP United States
- RCKT United States
- Employees
- RAMP N/A
- RCKT N/A
- Industry
- RAMP EDP Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- RCKT Health Care
- Exchange
- RAMP Nasdaq
- RCKT Nasdaq
- Market Cap
- RAMP 1.8B
- RCKT 264.0M
- IPO Year
- RAMP 1987
- RCKT N/A
- Fundamental
- Price
- RAMP $32.51
- RCKT $2.99
- Analyst Decision
- RAMP Buy
- RCKT Buy
- Analyst Count
- RAMP 8
- RCKT 13
- Target Price
- RAMP $39.38
- RCKT $18.50
- AVG Volume (30 Days)
- RAMP 493.9K
- RCKT 3.8M
- Earning Date
- RAMP 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- RAMP N/A
- RCKT N/A
- EPS Growth
- RAMP N/A
- RCKT N/A
- EPS
- RAMP N/A
- RCKT N/A
- Revenue
- RAMP $745,580,000.00
- RCKT N/A
- Revenue This Year
- RAMP $10.01
- RCKT N/A
- Revenue Next Year
- RAMP $9.39
- RCKT N/A
- P/E Ratio
- RAMP N/A
- RCKT N/A
- Revenue Growth
- RAMP 13.03
- RCKT N/A
- 52 Week Low
- RAMP $21.45
- RCKT $2.19
- 52 Week High
- RAMP $36.08
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- RAMP 50.93
- RCKT 45.55
- Support Level
- RAMP $33.18
- RCKT $2.76
- Resistance Level
- RAMP $34.50
- RCKT $3.24
- Average True Range (ATR)
- RAMP 0.87
- RCKT 0.19
- MACD
- RAMP -0.06
- RCKT 0.17
- Stochastic Oscillator
- RAMP 54.57
- RCKT 74.85
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.